LY500307
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LY500307, covering 2019-07-02 to 2019-07-02. Get the full timeline:
Most recent: Clinical Trial Update: The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia [Phase 2]